A second-generation cardiac myosin inhibitor showed promise for the treatment of obstructive hypertrophic cardiomyopathy (HCM) in the phase II REDWOOD-HCM trial. In the dose-finding study, 10 weeks of ...
– Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM – – Four-week treatment with EDG-7500 demonstrated ...
Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...
Pressure tracings made from the body of the left ventricle (LV) (A), the body and left ventricular outflow tract (LVOT) (B), and LV body and aorta (C). In B, both catheters record an LV pressure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results